Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...

Diabetic vitreous hemorrhage is linked to neuropathologic changes in specific brain regions, as identified by voxel-based ...

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), a biopharmaceutical ...

The following is a summary of “Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study,” published in the January 2025 issue of Ophthalmology by ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye disorders. "We ...

If you have diabetes, following a nutritious diet that promotes healthy blood sugar levels is critical. But it can feel challenging to constantly shop for, plan, and prepare diabetes-friendly ...

Opus Genetics, Inc. (NASDAQ:IRD), a pharmaceutical preparations company with a market capitalization of $36.3 million, has updated its executive employment agreements, enhancing severance terms for ...

The 1-year results from the HELIOS Trial that evaluated the investigational intravitreal AXPAXLI implant (OTX-TKI, Ocular Therapeutix) for the treatment of non-proliferative diabetic retinopathy (NPDR ...